42.09

1.13% 0.32

Sionna Therapeutics Inc (SION)

Overview News Price History Discussions Forecast

Sionna Therapeutics Inc stock is traded at $42.09, with a volume of 96,531. It is up +1.13% in the last 24 hours and down -2.76% over the past month. Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Previous Close:

$41.77

Open:

$41.3

24h Volume:

96,531

Relative Volume:

0.32

Market Cap:

$1.89B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+8.00%

1M Performance:

-2.76%

6M Performance:

+113.66%

1Y Performance:

+0.00%

1-Day Range:

$41.30

$43.13

1-Week Range:

$37.70

$43.13

52-Week Range:

$7.255

$45.00

Sionna Therapeutics Inc Stock (SION) Company Profile

Name

Sionna Therapeutics Inc

Sector

Healthcare (1119)

Industry

Biotechnology (625)

Phone

617-819-2020

Address

21 HICKORY DRIVE, SUITE 500, WALTHAM

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SION's Discussions on Twitter

Compare SION with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SION Sionna Therapeutics Inc	42.30	1.86B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	463.83	118.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	749.34	79.40B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	811.57	51.18B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	360.84	48.88B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	339.19	37.49B	4.98B	69.59M	525.67M	0.5197

Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-01-25	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
Nov-19-25	Initiated	BTIG Research	Buy
Sep-03-25	Initiated	RBC Capital Mkts	Sector Perform
Sep-03-25	Initiated	Raymond James	Strong Buy
Mar-04-25	Initiated	Guggenheim	Buy
Mar-04-25	Initiated	Stifel	Buy
Mar-04-25	Initiated	TD Cowen	Buy

View All

Sionna Therapeutics Inc Stock (SION) Latest News

Jan 21, 2026

Aug Sentiment: Should you avoid Sionna Therapeutics Inc stock right now - baoquankhu1.vn

Jan 21, 2026

Jan 15, 2026

Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares - AOL.com

Jan 15, 2026

Jan 14, 2026

Sionna Therapeutics (NASDAQ:SION) Stock Price Up 8.1%Here's Why - MarketBeat

Jan 14, 2026

Multiple Shots on Goal in Cystic Fibrosis: Sionna’s NBD1-Targeted Pipeline and 2026 Clinical Readouts Drive Buy Thesis and $58 DCF-Based Target - TipRanks

Jan 14, 2026

BTIG Research Reiterates Buy Rating for Sionna Therapeutics (NASDAQ:SION) - MarketBeat

Jan 14, 2026

Jan 13, 2026

SION: Advancing NBD1 stabilizers to transform CF care, with key data expected mid-2026 - TradingView — Track All Markets

Jan 13, 2026

SION: First-in-class NBD1 stabilizers target full CFTR correction, with pivotal data expected mid-2026 - TradingView — Track All Markets

Jan 13, 2026

Jan 12, 2026

Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.1%Here's What Happened - MarketBeat

Jan 12, 2026

Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B Multiple - Yahoo Finance

Jan 12, 2026

Jan 10, 2026

Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study - MSN

Jan 10, 2026

Jan 09, 2026